The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Anti‐CRISPR proteins targeting the CRISPR‐Cas system enrich the toolkit for genetic engineering
Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas adaptive immune defense systems, which are widely distributed in bacteria and Archaea, can provide sequence‐specific protection against foreign DNA or RNA in some cases. However, the evolution of defense systems in bacterial hosts did not lead to the elimination of phages, and some phages carry anti‐CRISPR genes that encode products that bind to the components mediating the defense mechanism and thus antagonize CRISPR‐Cas immune systems of bacteria. Given the extensive application of CRISPR‐Cas9 technologies in gene editing, in this review, we focus on the anti‐CRISPR proteins (Acrs) that inhibit CRISPR‐Cas systems for gene editing. We describe the discovery of Acrs in immune systems involving type I, II, and V CRISPR‐Cas immunity, discuss the potential function of Acrs in inactivating type II and V CRISPR‐Cas systems for gene editing and gene modulation, and provide an outlook on the development of important biotechnology tools for genetic engineering using Acrs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are a recently discovered method to reduce off-target effects of CRISPR/Cas-9.74”
From Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing (2021) · cites this paper as [74]
In the citing paper
“Anti-CRISPR (Acr) proteins are phage derived small proteins that inhibit the activity of CRISPR/Cas system.”
From Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing (2021) · cites this paper as [74]
Citations
Cites
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Diversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423
Schneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing
Edraki, A., Mir, A., Ibraheim, R., Gainetdinov, I., Yoon, Y., Song, C.-Q., Cao, Y., Gallant, J., Xue, W., Rivera-Pérez, J. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.003 · Cited by 265
Research works printed but not linked: 113
- 10.1038/nbt.2842 · DOI · Paper page
- 10.1016/j.virusres.2017.07.020 · DOI
- Wong TWY, 2017, Therapeutic applications of CRISPR/Cas for duchenne muscular dystrophy, Curr Gene Ther, 17, 301
- 10.1038/cgt.2015.54 · DOI
- 10.3390/cancers11091260 · DOI
- 10.1038/nrmicro2315 · DOI
- 10.1128/MMBR.00011-16 · DOI
- 10.1016/j.coi.2011.10.005 · DOI
- 10.1126/science.1138140 · DOI · Paper page
- 10.1016/j.mib.2017.06.003 · DOI
- 10.1038/nrmicro3241 · DOI
- 10.1038/nature11723 · DOI
- 10.1128/mBio.00896-14 · DOI
- 10.1038/nrmicro3569 · DOI · Paper page
- 10.1038/s41564-017-0004-7 · DOI
- 10.1038/nmicrobiol.2016.85 · DOI
- 10.1038/s41467-018-05092-w · DOI
- 10.1038/s41564-018-0120-z · DOI
- 10.1126/science.aau5138 · DOI
- 10.1016/j.cell.2016.12.009 · DOI
- 10.1126/science.aau5174 · DOI
- 10.1016/j.cell.2016.11.017 · DOI
- 10.1016/j.cell.2019.09.003 · DOI
- 10.1038/nrmicro.2017.120 · DOI
- 10.1146/annurev-genet-120417-031321 · DOI
- 10.1146/annurev-virology-101416-041616 · DOI
- 10.1016/j.molcel.2017.09.002 · DOI
- 10.1093/femsle/fnz098 · DOI
- 10.1128/jb.169.12.5429-5433.1987 · DOI · Paper page
- 10.1038/nrmicro2577 · DOI · Paper page
- 10.1093/nar/gkt157 · DOI
- 10.1038/ncomms10613 · DOI
- 10.1038/nature09523 · DOI
- 10.1146/annurev-genet-110711-155447 · DOI
- 10.1126/science.1225829 · DOI · Paper page
- 10.1038/nbt.3659 · DOI · Paper page
- 10.1016/j.molcel.2015.02.032 · DOI
- 10.1016/j.cell.2015.12.035 · DOI · Paper page
- 10.1099/mic.0.023960-0 · DOI · Paper page
- 10.1038/nature13579 · DOI · Paper page
- 10.1016/j.cell.2015.04.027 · DOI · Paper page
- 10.1016/j.molcel.2014.10.005 · DOI
- 10.1016/j.molcel.2014.09.027 · DOI
- 10.1111/mmi.12152 · DOI
- 10.1093/nar/gku1302 · DOI
- 10.1016/j.cell.2015.09.038 · DOI · Paper page
- 10.1038/nature13589 · DOI · Paper page
- Wei LC, 2017, Immunity to CRISPR Cas9 and Cas12a therapeutics, Wiley Interdiscip Rev Syst Biol Med, 10, e1408
- 10.1128/mBio.02321-18 · DOI
- 10.1371/journal.pgen.1003454 · DOI
- 10.1038/ncomms5399 · DOI
- Wandera KG, 2019, An enhanced assay to characterize anti‐CRISPR proteins using a cell‐free transcription‐translation system, Methods, 19, S1046
- 10.1016/j.molcel.2017.12.007 · DOI
- 10.1016/j.chom.2019.01.003 · DOI
- 10.7554/eLife.46540 · DOI
- 10.1016/j.cell.2017.07.037 · DOI
- 10.1016/j.chom.2012.06.003 · DOI
- 10.1128/JB.00644-10 · DOI
- 10.1126/science.1165771 · DOI · Paper page
- 10.1128/MMBR.00044-12 · DOI
- 10.1073/pnas.1320952111 · DOI
- 10.1038/nature15254 · DOI
- 10.1016/j.cell.2017.09.006 · DOI
- 10.1016/j.cell.2017.03.012 · DOI
- 10.1038/cr.2017.79 · DOI
- 10.1038/nsmb.3269 · DOI
- 10.1073/pnas.1618421114 · DOI
- 10.1073/pnas.1616395114 · DOI
- 10.1016/j.molcel.2019.02.001 · DOI
- 10.1128/mBio.01751-17 · DOI
- 10.1016/j.molcel.2019.01.038 · DOI
- 10.1038/s41467-019-10577-3 · DOI
- 10.1111/febs.15037 · DOI
- 10.1093/nar/gkx1181 · DOI
- 10.1016/j.molcel.2018.11.011 · DOI
- 10.1099/mic.0.000635 · DOI
- 10.1016/j.molcel.2018.11.016 · DOI
- 10.1016/j.molcel.2017.05.024 · DOI
- 10.1038/nature22377 · DOI
- 10.1126/sciadv.1701620 · DOI
- 10.1038/s41594-019-0208-z · DOI
- 10.1016/j.chom.2019.05.004 · DOI
- 10.7554/eLife.49110 · DOI
- 10.1073/pnas.1909400116 · DOI
- 10.1038/s41594-019-0206-1 · DOI
- 10.1038/s41426-018-0169-z · DOI
- 10.1186/s12976-018-0079-8 · DOI
- 10.1002/jcp.27476 · DOI
- 10.1126/science.1258096 · DOI · Paper page
- 10.1146/annurev-biochem-060815-014607 · DOI
- 10.1016/j.celrep.2018.01.045 · DOI
- 10.1038/s41467-018-06129-w · DOI
- 10.1186/s13059-015-0846-3 · DOI
- 10.1002/anie.201512002 · DOI
- 10.1038/nbt.3290 · DOI · Paper page
- 10.1038/s41467-018-05641-3 · DOI · Paper page
- 10.1016/j.celrep.2018.11.079 · DOI
- 10.1021/acschembio.5b01019 · DOI
- 10.1016/j.copbio.2017.03.025 · DOI
- 10.1038/s41467-018-08158-x · DOI
- 10.1021/acschembio.7b00831 · DOI
- Hoffmann MD, 2019, Cell‐specific CRISPR‐Cas9 activation by microRNA‐dependent expression of anti‐CRISPR proteins, Mol Ther, 27, 296
- 10.1093/nar/gkx309 · DOI
- 10.1021/acssynbio.9b00073 · DOI
- 10.1261/rna.071704.119 · DOI · Paper page
- 10.1038/s41592-018-0178-9 · DOI
- 10.1016/j.omtm.2018.04.008 · DOI
- 10.1016/j.bios.2019.111361 · DOI
- 10.1038/srep38169 · DOI
- 10.1038/nbt.3737 · DOI · Paper page
- 10.1038/nbt.3614 · DOI
- 10.1016/j.cell.2019.04.009 · DOI
- 10.1089/nat.2018.0758 · DOI
Cited by
Sorted by citations
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing
Mengstie, M. A., & Wondimu, B. Z. (2021) · Biologics: Targets and Therapy · doi:10.2147/btt.s326422 · Cited by 478
Metadata
- Authors
- Liu, Q., Zhang, H., & Huang, X.
- Affiliations
- Department of Medical Microbiology School of Medicine Nanchang University China
- ORCID
- Huang, Xiaotian
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2019-11-29
- Volume
- 287
- Issue
- 4
- Pages
- 626-644
- ISSN
- 1742-464X
- 1742-4658
- Cited by
- 31
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐CRISPR proteins targeting the CRISPR‐Cas system enrich the toolkit for genetic engineering. https://app.cochat.ai/papers/10.1111/febs.15139
- The paper
- Liu, Q., Zhang, H., & Huang, X. (2020). Anti‐CRISPR proteins targeting the CRISPR‐Cas system enrich the toolkit for genetic engineering. The FEBS Journal. https://doi.org/10.1111/febs.15139
